Ignite Creation Date:
2024-05-06 @ 6:16 PM
Last Modification Date:
2024-10-26 @ 2:44 PM
Study NCT ID:
NCT05601219
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-11-09
First Post:
2022-10-17
Brief Title:
A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors
Sponsor:
Adanate Inc
Organization:
Adanate Inc
Study Overview
Official Title:
A Phase 1 Open-Label Multicenter Study of ADA-011 as Monotherapy and in Combination With a Checkpoint Inhibitor for Subjects With Advanced Solid Tumors
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study consists of dose escalation evaluation to determine the safety and tolerability of ADA-011 as a monotherapy Following dose escalation one or more dose expansion cohorts in selected indications will be explored to further evaluate the safety tolerability and preliminary efficacy of ADA-011
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None